Fate Therapeutics Inc
FATE
查看详细走势图
1.185USD
-0.005-0.42%
收盘 01/30, 16:00（美东）报价延迟15分钟
136.67M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.42%
5天
-5.20%
1月
+18.80%
6月
+1.28%
今年开始到现在
+20.60%
1年
-9.54%
查看详细走势图
TradingKey Fate Therapeutics Inc股票评分
单位: USD 更新时间: 2026-01-29操作建议
Fate Therapeutics Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名99/393位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.94。中期看，股价处于下降通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Fate Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Fate Therapeutics Inc亮点
亮点风险
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
分析师目标
根据
12
位分析师
买入
评级
4.944
目标均价
+277.44%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Fate Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Fate Therapeutics Inc简介
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
公司代码FATE
公司Fate Therapeutics Inc
CEOValamehr (Bahram)
网址https://fatetherapeutics.com/
相关品种
